181 related articles for article (PubMed ID: 34413127)
1. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
Schultz CW; McCarthy GA; Nerwal T; Nevler A; DuHadaway JB; McCoy MD; Jiang W; Brown SZ; Goetz A; Jain A; Calvert VS; Vishwakarma V; Wang D; Preet R; Cassel J; Summer R; Shaghaghi H; Pommier Y; Baechler SA; Pishvaian MJ; Golan T; Yeo CJ; Petricoin EF; Prendergast GC; Salvino J; Singh PK; Dixon DA; Brody JR
Mol Cancer Ther; 2021 Nov; 20(11):2166-2176. PubMed ID: 34413127
[TBL] [Abstract][Full Text] [Related]
2. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma.
Ponzini FM; Schultz CW; Leiby BE; Cannaday S; Yeo T; Posey J; Bowne WB; Yeo C; Brody JR; Lavu H; Nevler A
BMJ Open; 2023 Oct; 13(10):e073839. PubMed ID: 37848297
[TBL] [Abstract][Full Text] [Related]
3. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer.
Xu W; Lacerda L; Debeb BG; Atkinson RL; Solley TN; Li L; Orton D; McMurray JS; Hang BI; Lee E; Klopp AH; Ueno NT; Reuben JM; Krishnamurthy S; Woodward WA
PLoS One; 2013; 8(8):e71508. PubMed ID: 24013655
[TBL] [Abstract][Full Text] [Related]
4. An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system--a unique mitochondrial energy metabolism in tumour microenvironments.
Tomitsuka E; Kita K; Esumi H
J Biochem; 2012 Aug; 152(2):171-83. PubMed ID: 22528668
[TBL] [Abstract][Full Text] [Related]
5. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
6. Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment.
Nair RR; Piktel D; Hathaway QA; Rellick SL; Thomas P; Saralkar P; Martin KH; Geldenhuys WJ; Hollander JM; Gibson LF
Pharm Res; 2020 Jan; 37(3):43. PubMed ID: 31989336
[TBL] [Abstract][Full Text] [Related]
7. An anthelmintic drug, pyrvinium pamoate, thwarts fibrosis and ameliorates myocardial contractile dysfunction in a mouse model of myocardial infarction.
Murakoshi M; Saiki K; Urayama K; Sato TN
PLoS One; 2013; 8(11):e79374. PubMed ID: 24223934
[TBL] [Abstract][Full Text] [Related]
8. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
[TBL] [Abstract][Full Text] [Related]
9. The novel role of pyrvinium in cancer therapy.
Momtazi-Borojeni AA; Abdollahi E; Ghasemi F; Caraglia M; Sahebkar A
J Cell Physiol; 2018 Apr; 233(4):2871-2881. PubMed ID: 28500633
[TBL] [Abstract][Full Text] [Related]
10. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses.
Shinkawa T; Ohuchida K; Mochida Y; Sakihama K; Iwamoto C; Abe T; Ideno N; Mizuuchi Y; Shindo K; Ikenaga N; Moriyama T; Nakata K; Oda Y; Nakamura M
J Exp Clin Cancer Res; 2022 Mar; 41(1):89. PubMed ID: 35272688
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of pyrvinium pamoate on uveal melanoma cells involves blocking of Wnt/β-catenin pathway.
Zheng L; Liu Y; Pan J
Acta Biochim Biophys Sin (Shanghai); 2017 Oct; 49(10):890-898. PubMed ID: 28981601
[TBL] [Abstract][Full Text] [Related]
12. The impact of pyrvinium pamoate on colon cancer cell viability.
Wiegering A; Uthe FW; Hüttenrauch M; Mühling B; Linnebacher M; Krummenast F; Germer CT; Thalheimer A; Otto C
Int J Colorectal Dis; 2014 Oct; 29(10):1189-98. PubMed ID: 25060218
[TBL] [Abstract][Full Text] [Related]
13. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration.
Ishii I; Harada Y; Kasahara T
Front Oncol; 2012; 2():137. PubMed ID: 23061049
[TBL] [Abstract][Full Text] [Related]
14. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
15. Pyrvinium pamoate ameliorates cyclosporin A- induced hepatotoxicity via the modulation of Wnt/β-catenin signaling and upregulation of PPAR-γ.
Faheem SA; El-Sayed NM; Moustafa YM; Saeed NM; Hazem RM
Int Immunopharmacol; 2022 Mar; 104():108538. PubMed ID: 35074592
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder.
Guo J; Lv J; Chang S; Chen Z; Lu W; Xu C; Liu M; Pang X
Oncotarget; 2016 Jul; 7(29):45249-45262. PubMed ID: 27303922
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
19. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
20. Pyrvinium pamoate inhibits cell proliferation through ROS-mediated AKT-dependent signaling pathway in colorectal cancer.
Zheng W; Hu J; Lv Y; Bai B; Shan L; Chen K; Dai S; Zhu H
Med Oncol; 2021 Feb; 38(2):21. PubMed ID: 33554313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
